Eyeworld

Actual size 1.8mm x 0.5mm The catalyst to advance the interventional glaucoma revolution. Designed to deliver long duration PGA therapy intracamerally with proven safety and patient tolerability. 1,2 1. Data on file, Glaukos Corporation. 2. iDose TR (travoprost intracameral implant) 75 mcg Prescribing Information. Glaukos Corporation. 2023. SHATTERING THE STATUS QUO INTERVENTIONAL GLAUCOMA Please see Important Safety Information on the reverse side. Real image of glaucoma eye drop Actual size 1.8mm x 0.5mm Real image of iDose TR (60x magnification of all images) for the reduction of IOP in patients with OAG and OHT 1 FDA-APPROVED Introducing iDose TR – the revolutionary way to deliver 24/7, long duration prostaglandin analog therapy intracamerally with proven safety and patient tolerability. 1,2 INDICATIONS AND USAGE iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT). IMPORTANT SAFETY INFORMATION DOSAGE AND ADMINISTRATION For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions. CONTRAINDICATIONS iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch's Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet's Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product. WARNINGS AND PRECAUTIONS iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent. ADVERSE REACTIONS In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity. Please see full Prescribing Information. You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644. View full prescribing information at iDoseTRhcp.com 1. Data on file, Glaukos Corporation. 2. iDose TR (travoprost intracameral implant) 75 mcg Prescribing Information. Glaukos Corporation. 2023. ©2025 Glaukos Corporation. All rights reserved. Glaukos and iDose are registered trademarks of Glaukos Corporation. PM-US-2525

• Cover